Lymphocyte immunization therapy in patients with recurrent implantation failure.

Evaluating the Efficacy of Lymphocyte Immunization Therapy in Improving Ongoing Pregnancy Rates in Women with Recurrent Pregnancy Loss and Implantation Failure: A Prospective Interventional Single Arm Study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076768

Enrollment

Registered

2024-11-13

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N978- Female infertility of other origin

Interventions

Intervention1: Lymphocyte immunization therapy : The isolated lymphocytes are injected intradermally into the female partner, typically in the forearm. The procedure may be repeated at interval of 15

Eligibility

Inclusion criteria

Inclusion criteria: Recurrent Pregnancy Loss: Unexplained Infertility Repeated Implantation Failure High HLA match more than 2 alleles between the mother and father, especially HLA-C Negative CDC cross-match Negative ANA (antinuclear antibody)

Exclusion criteria

Exclusion criteria: Uncorrected Endocrine disorder Uncorrected Uterine Anomalies and Thin Endometrium less than 7mm APLA positivity and Systemic Autoimmune Conditions Women not willing for Immunological evaluation Untreated Chronic Endometritis Transfer of Embryo Grade C or D

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of LIT in improving ongoing Pregnancy rates (12 weeks) in women with unexplained RPL and RIF. Timepoint: 12 weeks	—

Secondary

Measure	Time frame
To investigate the HLA , CDC cross match , Immuno profiling as pre-indications of LIT To evaluate changes in immune profiling following LIT. Timepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDrGokul

A4 Hospital and Fertility centre

gokulrams1996@gmail.com09841269578

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026